The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal Phase III study

International Journal of Stroke

Volumn 6, Issue 4, 2011, Pages 362-367

  Rosenberg, Gilad ^a   Bornstein, Natan ^b   Diener, Hans Christoph ^c   Gorelick, Philip B ^d   Shuaib, Ashfaq ^e   Lees, Kennedy ^f  

^a D Pharm Ltd   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF ILLINOIS   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Acute stroke therapy; Cerebral infarction; Clinical trial; Ischemic stroke; Neuroprotection; Protocols

Indexed keywords

ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LANGUAGE DISABILITY; MALE; MEMBRANE ACTIVATED CHELATOR STROKE INTERVENTION TRIAL; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHELATING AGENTS; DOUBLE-BLIND METHOD; EGTAZIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; RESEARCH DESIGN; STROKE; YOUNG ADULT;

EID: 79960274195     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00608.x     Document Type: Article

References (32)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747-57.
2. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8:355-69.
3. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121:e46-215.
4. Galasso SL, Dyck RH. The role of zinc in cerebral ischemia. Mol Med 2007; 13:380-7.
5. Barkalifa R, Hershfinkel M, Friedman JE, Kozak A, Sekler I. The lipophilic zinc chelator DP-b99 prevents zinc induced neuronal death. Eur J Pharmacol 2009; 618:15-21.
6. Angel I, Bar A, Horovitz T et al. Metal ion chelation in neurodegenerative disorders. Drug Dev Res 2002; 56:300-9.
7. Striem S, Schatz G, Krakovsky M et al. The effect of DP-b99, a lipophilic divalent transition metal chelator, on Matrix Metalloproteinases-2 and-9 activity in a rat MCAO ischemic model. Neural Plast 2003; 10:234 (abstract).
8. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 2008; 39:1774-8.
9. Rosenberg G, Angel I, Kozak A. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans. Br J Clin Pharmacol 2005; 60:7-16.
10. Rosenberg G AI, Kozak A, Schneider D. Evaluation of safety and changes in the NIH stroke scale, Rankin and Barthel scores following DP-b99 administration to acute stroke patients. Stroke 2004; 35:338 (abstract).
11. Adams HP, del, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups:the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-711.
12. European Sroke Organization (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457-507.
13. Quinn TJ, Lees KR, Hardemark HG, Dawson J, Walters MR. Initial experience of a digital training resource for modified Rankin scale assessment in clinical trials. Stroke 2007; 38:2257-61.
14. Sorani MD, Morabito D, Rosenthal G, Giacomini KM, Manley GT. Characterizing the dose-response relationship between mannitol and intracranial pressure in traumatic brain injury patients using a high-frequency physiological data collection system. J Neurotrauma 2008; 25:291-8.
15. Quinn TJ, Dawson J, Lees JS, Chang TP, Walters MR, Lees KR. Time spent at home poststroke: "home-time" a meaningful and robust outcome measure for stroke trials. Stroke 2008; 39:231-3.
16. ®: A Practical Guide. Cary, NC: SAS Institute Inc., 2005: 246-9.
17. Neff SR. Rodent models of stroke. Arch Neurol 1997; 54:350-1.
18. Weimar C, Ho TW, Katsarava Z, Diener HC. Improving patient selection for clinical acute stroke trials. Cerebrovasc Dis 2006; 21:386-92.
19. Davis SM, Donnan GA. Why lacunar syndromes are different and important. Stroke 2004; 35:1780-1.
20. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004; 1:36-45.
21. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007; 61:396-402.
22. Kane I, Whiteley WN, Sandercock PA, Wardlaw JM. Availability of CT and MR for assessing patients with acute stroke. Cerebrovasc Dis 2008; 25:375-7.
23. Leys D, Ringelstein EB, Kaste M, Hacke W. Facilities available in European hospitals treating stroke patients. Stroke 2007; 38:2985-91.
24. Yang ZH, Zhao XQ, Wang CX, Chen HY, Zhang YM. Neuroanatomic correlation of the post-stroke aphasias studied with imaging. Neurol Res 2008; 30:356-60.
25. Worrall BB, Farace E, Hillis AE et al. Correlation of aphasia and/or neglect with cortical infarction in a subpopulation of RANTTAS. Cerebrovasc Dis 2001; 11:257-64.
26. Leira EC, Adams HP, Rosenthal GE, Torner JC. Baseline NIH stroke scale responses estimate the probability of each particular stroke subtype. Cerebrovasc Dis 2008; 26:573-7.
27. Townend BS, Sturm JW, Petsoglou C, O'Leary B, Whyte S, Crimmins D. Perimetric homonymous visual field loss post-stroke. J Clin Neurosci 2007; 14:754-6.
28. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008; 39:924-8.
29. Boode B, Welzen V, Franke C, van Oostenbrugge R. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis 2007; 23:294-8.
30. Weimar C, Kraywinkel K, Maschke M, Diener HC. Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator. Cerebrovasc Dis 2006; 22:429-31.
31. Savitz SI, Schäbitz WR. A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke. Stroke 2008; 39:1389-91.
32. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007; 38:3055-62.